News
When researchers analyzed the group of patients who only met the CT criteria for suspected bronchiectasis, they found that those with normal spirometry (n = 731) showed a lower difference in 10 ...
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for brensocatib for patients with non-cystic fibrosis bronchiectasis. Bronchiectasis is a ...
The time to first bronchiectasis exacerbation was significantly longer in the brensocatib-treated patients compared with those in the placebo group (10 mg treatment hazard ratio [HR] 0.58, 95% CI ...
Session ID: 2025-06-16:7c54e923d7ee1e0c5453a5ff Player Element ID: vjs_video_3 ...
Session ID: 2025-07-28:438ebd2caae66a0797e3fc0 Player Element ID: vjs_video_3 ...
LOS ANGELES — For patients with non–cystic fibrosis bronchiectasis, an investigational inhaled powder form of ciprofloxacin can significantly reduce the frequency of exacerbations, results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results